Literature DB >> 11796474

The heparin anti-Xa therapeutic range: are we there yet?

Maureen A Smythe, Joan C Mattson, John M Koerber.   

Abstract

Mesh：

Substances：

Year:  2002        PMID： 11796474     DOI： 10.1378/chest.121.1.303

Source DB:  PubMed          Journal:  Chest        ISSN： 0012-3692            Impact factor:   9.410


× No keyword cloud information.
  3 in total

1.  From Activated Partial Thromboplastin Time to Antifactor Xa and Back Again.

Authors:  Jori E May; Rance Chad Siniard; Laura J Taylor; Marisa B Marques; Radhika Gangaraju
Journal:  Am J Clin Pathol       Date:  2022-03-03       Impact factor: 5.400

Review 2.  Guidance for the practical management of the heparin anticoagulants in the treatment of venous thromboembolism.

Authors:  Maureen A Smythe; Jennifer Priziola; Paul P Dobesh; Diane Wirth; Adam Cuker; Ann K Wittkowsky
Journal:  J Thromb Thrombolysis       Date:  2016-01       Impact factor: 2.300

3.  Evaluation of Antifactor-Xa Heparin Assay and Activated Partial Thromboplastin Time Values in Patients on Therapeutic Continuous Infusion Unfractionated Heparin Therapy.

Authors:  Kevin McLaughlin; Jessica Rimsans; Katelyn W Sylvester; John Fanikos; David M Dorfman; Patricia Senna; Jean M Connors; Samuel Z Goldhaber
Journal:  Clin Appl Thromb Hemost       Date:  2019 Jan-Dec       Impact factor: 2.389
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.